Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Congresses

View More Arrow
Congress-HFA

Transthyretin Amyloidosis (ATTR)

Heart Failure Association (HFA) 2026

May 9-12, 2026 Spain

View Details
Congress-AAN

Transthyretin Amyloidosis (ATTR)

American Academy of Neurology (AAN) 2026

April 18-22, 2026 USA

View Details
Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR)

American College of Cardiology (ACC) 2026

March 28-30, 2026 USA

View Details
Congress-ISPOR-Mobile

Transthyretin Amyloidosis (ATTR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025

November 9-12, 2025 UK

View Details
Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR)

American Heart Association (AHA) 2025

November 7-10, 2025 USA

View Details
Congress-HFSA-Mobile

Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

September 26-29, 2025 USA

View Details

Publications

View More Arrow

Transthyretin Amyloidosis (ATTR)

Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE

Clinical Medicine Insights: Cardiology

Author(s)

Jose Nativi-Nicolau, Johana Fajardo, Alyssa Galloway, et al

April 2026

Transthyretin Amyloidosis (ATTR)

Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study

European Journal of Heart Failure

Author(s)

Yasuhiro Hamatani, Brian L Claggett, Muthiah Vaduganathan, et al

March 2026

Transthyretin Amyloidosis (ATTR)

Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A

Neurology and Therapy

Author(s)

Jeeyoung Oh, Yoshiki Sekijima, Hideki Mochizuki, et al

March 2026

Transthyretin Amyloidosis (ATTR)

Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial

European Journal of Heart Failure

Author(s)

Awais Sheikh, Zi Michael Miao, Brian Claggett, et al

October 2025

Transthyretin Amyloidosis (ATTR)

Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis

Journal of Clinical Medicine

Author(s)

Akash Singh, John Wyatt, Marie Théaudin, et al

September 2025

Transthyretin Amyloidosis (ATTR)

Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study

Annals of Medicine

Author(s)

Yessar Hussain, Saurabh Malhotra, Brett W. Sperry, et al

September 2025